Table 3.
Among Primary Care Patients Diagnosed with OUDs in 6 Healthcare Systems, Percentage Office-Based Medications for OUD by HCV and HIV Status
| HCV only (n = 1194) |
HIV only (n = 94) |
Both HCV and HIV (n = 37) |
Neither HCV nor HIV (n = 12,462) |
|
|---|---|---|---|---|
| Medication type* | % (95% CI) | |||
| Buprenorphine | 19.1 (16.9, 21.4) | 11.7 (6.0, 20.0) | 10.8 (3.0, 25.4) | 20.3 (19.6, 21.0) |
| Oral naltrexone | 1.8 (1.1, 2.7) | 3.2 (0.7, 9.0) | 0.0 (0.0, 9.5) | 2.5 (2.2, 2.8) |
| Injectable naltrexone | 1.1 (0.6, 1.9) | 1.1 (0.0, 5.8) | 0.0 (0.0, 9.5) | 0.9 (0.8, 1.1) |
| Any office-based medication treatment for OUD | 20.9 (18.6, 23.3) | 16 (9.2, 25.0) | 10.8 (3.0, 25.4) | 22.3 (21.5, 23.0) |
*The number of patients on individual medications is not mutually exclusive as patients may have been ordered or dispensed more than one medication during the study period